151 related articles for article (PubMed ID: 12381789)
1. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma.
Hoyer KK; French SW; Turner DE; Nguyen MT; Renard M; Malone CS; Knoetig S; Qi CF; Su TT; Cheroutre H; Wall R; Rawlings DJ; Morse HC; Teitell MA
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14392-7. PubMed ID: 12381789
[TBL] [Abstract][Full Text] [Related]
2. T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
Gualco G; Weiss LM; Barber GN; Bacchi CE
Hum Pathol; 2010 Sep; 41(9):1238-44. PubMed ID: 20382409
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.
Shen RR; Ferguson DO; Renard M; Hoyer KK; Kim U; Hao X; Alt FW; Roeder RG; Morse HC; Teitell MA
Blood; 2006 Sep; 108(6):1991-8. PubMed ID: 16728701
[TBL] [Abstract][Full Text] [Related]
4. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma.
Said JW; Hoyer KK; French SW; Rosenfelt L; Garcia-Lloret M; Koh PJ; Cheng TC; Sulur GG; Pinkus GS; Kuehl WM; Rawlings DJ; Wall R; Teitell MA
Lab Invest; 2001 Apr; 81(4):555-64. PubMed ID: 11304575
[TBL] [Abstract][Full Text] [Related]
5. TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage.
Herling M; Patel KA; Hsi ED; Chang KC; Rassidakis GZ; Ford R; Jones D
Am J Surg Pathol; 2007 Jul; 31(7):1123-9. PubMed ID: 17592280
[TBL] [Abstract][Full Text] [Related]
6. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma.
Rathmell JC; Elstrom RL; Cinalli RM; Thompson CB
Eur J Immunol; 2003 Aug; 33(8):2223-32. PubMed ID: 12884297
[TBL] [Abstract][Full Text] [Related]
7. The role of TCL1 in human T-cell leukemia.
Pekarsky Y; Hallas C; Croce CM
Oncogene; 2001 Sep; 20(40):5638-43. PubMed ID: 11607815
[TBL] [Abstract][Full Text] [Related]
8. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
9. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation.
Rodig SJ; Vergilio JA; Shahsafaei A; Dorfman DM
Am J Surg Pathol; 2008 Jan; 32(1):113-22. PubMed ID: 18162778
[TBL] [Abstract][Full Text] [Related]
10. TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation.
Kuraishy AI; French SW; Sherman M; Herling M; Jones D; Wall R; Teitell MA
Proc Natl Acad Sci U S A; 2007 Jun; 104(24):10175-80. PubMed ID: 17548807
[TBL] [Abstract][Full Text] [Related]
11. TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma.
Teitell MA; Lones MA; Perkins SL; Sanger WG; Cairo MS; Said JW
Am J Clin Pathol; 2005 Oct; 124(4):569-75. PubMed ID: 16146820
[TBL] [Abstract][Full Text] [Related]
12. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.
Frank MJ; Dawson DW; Bensinger SJ; Hong JS; Knosp WM; Xu L; Balatoni CE; Allen EL; Shen RR; Bar-Sagi D; Martin GR; Teitell MA
Blood; 2009 Mar; 113(11):2478-87. PubMed ID: 19147787
[TBL] [Abstract][Full Text] [Related]
13. Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.
Johnston HE; Carter MJ; Cox KL; Dunscombe M; Manousopoulou A; Townsend PA; Garbis SD; Cragg MS
Mol Cell Proteomics; 2017 Mar; 16(3):386-406. PubMed ID: 28062796
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways.
Mathas S; Rickers A; Bommert K; Dörken B; Mapara MY
Cancer Res; 2000 Dec; 60(24):7170-6. PubMed ID: 11156427
[TBL] [Abstract][Full Text] [Related]
15. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma].
Shui RH; Lu HF; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):745-8. PubMed ID: 20079013
[TBL] [Abstract][Full Text] [Related]
17. Antigen receptor-mediated signaling pathways in transitional immature B cells.
Kövesdi D; Pászty K; Enyedi A; Kiss E; Matkó J; Ludányi K; Rajnavölgyi E; Sármay G
Cell Signal; 2004 Aug; 16(8):881-9. PubMed ID: 15157667
[TBL] [Abstract][Full Text] [Related]
18. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
[TBL] [Abstract][Full Text] [Related]
19. The protooncogene TCL1 is an Akt kinase coactivator.
Laine J; Künstle G; Obata T; Sha M; Noguchi M
Mol Cell; 2000 Aug; 6(2):395-407. PubMed ID: 10983986
[TBL] [Abstract][Full Text] [Related]
20. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis.
Schmidt T; Karsunky H; Gau E; Zevnik B; Elsässer HP; Möröy T
Oncogene; 1998 Nov; 17(20):2661-7. PubMed ID: 9840930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
